Community Trust & Investment Co. Trims Holdings in Eli Lilly and Company $LLY

Community Trust & Investment Co. lessened its position in Eli Lilly and Company (NYSE:LLY) by 2.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 23,391 shares of the company’s stock after selling 676 shares during the period. Eli Lilly and Company makes up 1.3% of Community Trust & Investment Co.’s investment portfolio, making the stock its 18th largest holding. Community Trust & Investment Co.’s holdings in Eli Lilly and Company were worth $25,138,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Carderock Capital Management Inc. boosted its stake in shares of Eli Lilly and Company by 9.2% during the 4th quarter. Carderock Capital Management Inc. now owns 12,184 shares of the company’s stock worth $13,094,000 after acquiring an additional 1,022 shares in the last quarter. jvl associates llc boosted its stake in Eli Lilly and Company by 4.8% in the 4th quarter. jvl associates llc now owns 547 shares of the company’s stock worth $588,000 after buying an additional 25 shares during the last quarter. Diversified Trust Co. grew its holdings in Eli Lilly and Company by 20.6% in the fourth quarter. Diversified Trust Co. now owns 23,635 shares of the company’s stock valued at $25,400,000 after purchasing an additional 4,043 shares during the period. Peterson Wealth Advisors LLC grew its position in Eli Lilly and Company by 2.5% during the fourth quarter. Peterson Wealth Advisors LLC now owns 865 shares of the company’s stock valued at $930,000 after acquiring an additional 21 shares during the period. Finally, Post Resch Tallon Group Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth $219,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Morgan Stanley reiterated an Overweight rating and a $1,313 price target, highlighting Lilly’s new employer access platform for obesity therapies and reinforcing bullish institutional support. Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform
• Positive Sentiment: Ongoing GLP‑1 strength is repeatedly cited as the core growth engine — multiple analyst/fund notes point to blockbuster obesity/weight‑management drugs as the main revenue driver. Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
• Positive Sentiment: Distribution expansion: Kroger pharmacies began offering Lilly’s Zepbound weight‑management product with support/savings programs, improving retail access and patient uptake prospects. What Kroger (KR)’s New Zepbound Access and Premium Ice Cream Push Means For Shareholders
• Positive Sentiment: Clinical progress: Lilly completed a pediatric pharmacokinetic (PK) study for a next‑gen diabetes candidate, de‑risking a development path that could broaden the diabetes portfolio. Lilly Advances Next-Gen Diabetes Drug With Completed Pediatric PK Study
• Positive Sentiment: Retail/influencer support: Jim Cramer and other high‑profile commentators continue to include LLY among top healthcare picks, adding retail momentum. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Zacks noted Lilly outpaced the market in the latest session, reflecting the mix of positive headlines but not adding new catalysts. Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
• Neutral Sentiment: Valuation/peer debate continues — analyses contrasting Lilly vs. Novo Nordisk and AbbVie focus investor attention on whether LLY’s premium multiple already prices in growth. Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity
• Negative Sentiment: Product rationalization risk: Lilly plans to phase out select insulin products across Europe by 2027 — could lower sales in that region and signals portfolio adjustments that investors should model. Eli Lilly to phase out select insulin products across Europe by 2027
• Negative Sentiment: Heightened public/policy scrutiny around GLP‑1s (societal obligation debate) could lead to reputational or reimbursement pressure even as sales grow. Eli Lilly and the ‘societal obligation’ of GLP-1s

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $915.71 on Thursday. The business’s 50-day simple moving average is $1,013.13 and its 200-day simple moving average is $961.39. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a market cap of $865.18 billion, a price-to-earnings ratio of 39.90, a P/E/G ratio of 1.05 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the prior year, the business earned $5.32 earnings per share. The company’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada began coverage on shares of Eli Lilly and Company in a report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $1,313.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 5th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 21st. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Finally, Wolfe Research boosted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,221.44.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.